NMI bladder cancer: which adjuvant intravesical therapy is best?

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • Compared with transurethral resection of the bladder tumor (TURBT) alone, intravesical bacillus Calmette-Guérin (BCG), mitomycin C (MMC), doxorubicin, and epirubicin were associated with reduced recurrence risk in non-muscle-invasive bladder cancer (NMIBC).  

 

Why this matters

  • Evidence suggests underuse of adjuvant intravesical therapy, which may be influenced by uncertainty regarding optimal treatment strategies.

Key results

  • Adjuvant BCG was associated with decreased recurrence (relative risk [RR], 0.56; I2=0%) and progression (RR, 0.39; I2=40%) vs TURBT alone. 
  • 1 trial found a nonstatistically significant trend toward decreased mortality with BCG induction therapy (RR, 0.62). 
  • MMC was associated with decreased recurrence (RR, 0.68; I2=74%). 
  • MMC was effective as maintenance (RR, 0.71; I2=6.8%) or single instillation therapy (RR, 0.45; I2=79%). 
  • Doxorubicin, epirubicin, interferon-alpha, and interferon-gamma were associated with decreased recurrence (pooled RRs, 0.63-0.80). 
  • Interferon-alpha was associated with decreased risk for progression (RR, 0.33; I2=0%). Thiotepa was associated with a nonstatistically significant decreased risk for recurrence (RR, 0.78; I2=69%). 
  • Recurrence risk was lower with BCG vs doxorubicin, epirubicin, interferon-alpha-2a, BCG plus interferon alpha-2b and thiotepa, but not MMC.

Study design

  • Meta-analysis of 39 studies published on multiple electronic databases. 
  • Funding: Agency for Healthcare Research and Quality.

Limitations

  • Heterogeneity between trials. 
  • Most trials had methodological limitations.